Zymergen (NASDAQ:ZY – Get Rating) will be releasing its earnings data after the market closes on Thursday, May 12th. Analysts expect Zymergen to post earnings of ($0.71) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Zymergen (NASDAQ:ZY – Get Rating) last issued its quarterly earnings data on Tuesday, March 22nd. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.13. The company had revenue of $3.04 million during the quarter, compared to analysts’ expectations of $2.83 million. Zymergen had a negative return on equity of 213.99% and a negative net margin of 2,160.81%. On average, analysts expect Zymergen to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of NASDAQ ZY opened at $1.76 on Thursday. The stock has a market cap of $181.50 million and a PE ratio of -0.18. The business has a fifty day moving average of $2.77 and a two-hundred day moving average of $5.78. Zymergen has a 52-week low of $1.54 and a 52-week high of $47.95.
In related news, CTO Aaron Kimball sold 32,639 shares of Zymergen stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $2.87, for a total value of $93,673.93. Following the completion of the sale, the chief technology officer now directly owns 712,644 shares in the company, valued at $2,045,288.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 48,015 shares of company stock valued at $150,032.
Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in Zymergen by 99.9% during the third quarter. Royal Bank of Canada now owns 2,561 shares of the company’s stock worth $34,000 after buying an additional 1,280 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Zymergen by 323.1% during the 4th quarter. Legal & General Group Plc now owns 6,715 shares of the company’s stock valued at $45,000 after purchasing an additional 5,128 shares in the last quarter. Amalgamated Bank bought a new position in shares of Zymergen during the 4th quarter valued at about $72,000. Squarepoint Ops LLC bought a new position in shares of Zymergen during the 4th quarter valued at about $81,000. Finally, Alliancebernstein L.P. bought a new position in shares of Zymergen during the 4th quarter valued at about $98,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.
About Zymergen (Get Rating)
Zymergen Inc design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems.
- Get a free copy of the StockNews.com research report on Zymergen (ZY)
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
Receive News & Ratings for Zymergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymergen and related companies with MarketBeat.com's FREE daily email newsletter.